Full-Time
Confirmed live in the last 24 hours
Quality and regulatory software solutions provider
$55k - $175kAnnually
Senior
Company Historically Provides H1B Sponsorship
Remote in USA
Veeva Systems offers software solutions for quality, regulatory, and advertising claims management, focusing on consumer products and chemical companies. Their cloud-based platform provides visibility and traceability throughout the product journey, helping clients ensure compliance with regulations while bringing products to market efficiently. Veeva stands out from competitors by addressing the specific challenges of the chemical and consumer goods industries, building on its experience in the life sciences sector. The company's goal is to support clients in delivering high-quality, safe, and sustainable products.
Company Size
5,001-10,000
Company Stage
IPO
Total Funding
$6.8M
Headquarters
Pleasanton, California
Founded
2007
Help us improve and share your feedback! Did you find this helpful?
Parental leave
PTO
Free food
Health, dental, & vision insurance
Gym membership reimbursement
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesINGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases."Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.""By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesLondon, UK — 11 March 2025 — Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development.With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimise trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.“Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world,” said Oliver Fink, head of learning, process and digitalisation at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.”“By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone toward realising Veeva and Boehringer’s shared mission to advance the use of data and technology to modernise clinical trials and deliver better patient outcomes.”Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain
Additionally, Veeva Systems secured its fourth top 20 customer in the Safety category and witnessed a top 20 customer commit comprehensively to its clinical solutions.
Fiscal Year 2025 Total Revenues of $2,746.6M, up 16% Year Over YearQ4 Total Revenues of $720.9M, up 14% Year Over Year. Fiscal Year 2025 Subscription Services Revenues of $2,284.7M, up 20% Year Over YearQ4 Subscription Services Revenues of $608.6M, up 17% Year Over Year. PLEASANTON, Calif., March 5, 2025 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2025
Veeva Systems (NYSE:VEEV) launches innovative CRM Pulse for global healthcare engagement metrics.